Every 10-Q that Cytokinetics Inc. (CYTK) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CYTK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CYTK filings page.
Cytokinetics (CYTK) reported Q3 2025 results marked by continued investment ahead of potential commercialization. Total revenue was $1.936 million, primarily from collaboration revenue. Operating expenses rose to $168.7 million, driving an operating loss of $166.8 million. Net loss widened to $306.2 million, reflecting a $121.2 million debt conversion expense tied to convertible notes activity.
Liquidity remained strong with cash, cash equivalents and investments of roughly $1.3 billion as of September 30, 2025. The balance sheet shows $1.958 billion in total liabilities, including $889.5 million in convertible notes, $158.7 million in term loans, and liabilities related to revenue participation agreements. Stockholders’ deficit was $(521.1) million. Year-to-date cash used in operations was $367.4 million.
The company continues late-stage development programs and notes a PDUFA target action date of December 26, 2025 for the NDA for aficamten in obstructive HCM. Common shares outstanding were 122,264,929 as of November 3, 2025.
Cytokinetics (CYTK) Q2-25 10-Q highlights: Revenue jumped to $66.8 m (Q2-24: $0.3 m) and $68.3 m for H1, driven by the Bayer Japan license (one-time $52.4 m recognition) and two €5 m milestones. Collaboration revenue remains modest. Operating loss narrowed to $111.5 m (-14% YoY), but six-month operating loss widened to $335.5 m. Net loss was $134.4 m for the quarter (-$1.12/sh) and $295.7 m YTD.
Balance sheet & liquidity: Cash, cash equivalents and investments total $1.0 bn, down from $1.2 bn at FY-24. Quarterly cash burn from operations was $259.9 m. Total liabilities rose to $1.59 bn (incl. $554 m convertible notes and $489 m revenue-participation liabilities) producing a stockholders’ deficit of $368.7 m. Additional $75 m was drawn on Royalty Pharma Tranche 4 in April; Tranche 5 ($100 m) remains available through Nov-25.
Pipeline/regulatory: NDA for aficamten in obstructive HCM accepted; PDUFA target date 26 Dec 2025. Phase 3 programs in non-obstructive HCM and pediatric HCM progressing. Omecamtiv mecarbil Greater China license terminated; rights reverted to CYTK. Cash runway expected to cover at least 12 months; management anticipates continued losses until commercial launch.